Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus indacaterol, glycopyrronium, and placebo in moderate to severe COPD
2012-003347-30Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol and glycopyrronium in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Novartis. Primary endpoint: Standardized FEV1 AUC0-12 at Week 12. Started Jan 2013; status: completed.
02
Drugs
indacaterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-003347-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003347-30.